SELENOV: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: SELENOV

NCBI ID: G348303

SELENOV

SELENOV: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Selenoprotein V (SPV) is a heat-labile protein that is expressed in most tissues of the body. It is one of the five known proteins that can cross the blood-brain barrier and play a role in the pathogenesis of Alzheimer's disease (AD).

AD is a neurodegenerative disorder that affects millions of people worldwide, characterized by the progressive accumulation of neurofibrillary tangles and senile plaques in the brain. The most common cause of AD is the presence of SPV-containing aggregates, which are thought to play a role in the destruction of nerve cells in the brain.

Recent studies have suggested that SPV may be a drug target and biomarker for AD. SPV has been shown to be involved in the development and progression of neurofibrillary tangles and senile plaques, and it has been shown to interact with several proteins that are known to be involved in the development and progression of AD.

One of the proteins that has been shown to interact with SPV is the protein tau. Tau is a protein that is involved in the formation of neurofibrillary tangles and is often knocked down in AD. SPV has been shown to reduce the levels of tau in brain tissue, which may indicate that it has a positive impact on the levels of tau in the brain.

Another protein that has been shown to interact with SPV is the protein presenilin-1. Presenilin-1 is a protein that is involved in the formation of neurofibrillary tangles and is often increased in AD. SPV has been shown to decrease the levels of presenilin- 1 in brain tissue, which may indicate that it has a negative impact on the levels of presenilin-1 in the brain.

In addition to interacting with tau and presenilin-1, SPV has also been shown to interact with several other proteins that are involved in the development and progression of AD. These include the protein brain-derived neurotrophic factor (BDNF), the protein nitric oxide (NO), and the protein microtubule-associated protein 2 (MAP2).

SPV has also been shown to play a role in the development of neurodegeneration in the brain. Studies have shown that SPV-containing aggregates are highly sensitive to ischemia/reperfusion injury, which is a common cause of neurodegeneration. This suggests that SPV may be involved in the development of neurodegeneration in the brain.

Given the involvement of SPV in the development and progression of AD, it is a promising target for drug development. Studies have shown that SPV can be effectively targeted with small molecules, antibodies, and other therapeutic agents. In addition, SPV has been shown to be a biomarker for the early detection of AD, which may be useful for the diagnosis and prognosis of this disease.

In conclusion, SPV is a promising drug target and biomarker for AD. Its involvement in the development and progression of neurofibrillary tangles and senile plaques, as well as its interaction with tau, presenilin-1, and other proteins involved in the pathogenesis of AD, makes it an attractive target for drug development. Additionally, its role as a biomarker for the early detection of AD may be useful for the diagnosis and prognosis of this disease. Further studies are needed to fully understand the role of SPV in the pathogenesis of AD and its potential as a drug target and biomarker.

Protein Name: Selenoprotein V

Functions: May be involved in a redox-related process

The "SELENOV Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SELENOV comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets